KR890003732A - New Pharmaceutical Compound - Google Patents

Abstract

No content

Description

New Pharmaceutical Compound

Since this is an open matter, no full text was included.

Claims (9)

A compound of formula (I) or a physiologically acceptable salt thereof. Wherein Q and Q ¹ -Q ⁸ are hydrogen; A is a group of -CONQ ⁹ (CH ₂ ) _n- , n is 4 and Q ⁹ is hydrogen; B is isopropyl group; E is a carboxyl group; Z is carboxyl or A C _2-5 carboalkoxy group, D is a methyl group, (X) is a naphthyl or indolyl ring system; Is a pyrrolidinyl ring; When (X) is a naphthyl ring system, the compound of formula (I) is N- (1 (S) -carboxy-5- [5- (2 (R, S) -hydroxy-3-isopropylamino propoxy) ) Naphth-2-ylcarboxamido] pentyl)-(R, S) -alanyl- (S) -proline or N- (1 (S) -carboxy-5- [8- (2 (R, S) ) -Hydroxy-3-isopropylamino propoxy) naphth-2-ylcarboxamido pentyl)-(R, S) -alanyl- (S) -proline or a half ester thereof, wherein Z is C _{2 -6} carboalkoxy) and (X) is an indolyl ring system, the compound of formula (I) is N- (1 (S) -carboxy-5- [4- (2 (S) -hydroxy-3-iso) Propylamino propoxy-1H-indol-2-yl-carboxamido] pentyl)-(S) -alanyl- (S) -proline, or a half ester thereof (Z is C _2-6 carboalkoxy) to be. The compound of formula (I) or a physiologically acceptable salt thereof according to claim 1 for use in medical treatment. The compound of formula (I) or a physiologically acceptable salt thereof according to claim 1 for use in the prevention or treatment of cardiovascular disease, excessive aldosterone, glaucoma, migraine, and the like. A compound of formula (I) or a physiologically acceptable salt thereof according to claim 1 for the prevention or treatment of cardiovascular diseases such as hypertension, congestive cardiac insufficiency, myocardial infarction or hypotension. The compound of formula (I) or a physiologically acceptable salt thereof according to claim 1 for use in the prevention or treatment of hypotension of angina pectoris. The method of claim 1, wherein N- (1 (S) -carboxy-5- [5- (2 (R, S)-) for use in the prophylaxis or treatment of the disease or disease syndrome referred to in claims 3 to 5. Hydroxy-3-isopropylamino propoxy) naphth-2-ylcarboxamido] pentyl)-(R, S) -alanyl- (S) -proline, N- (1 (S) -carboxy-5 -[8- (2 (R, S) -Hydroxy-3-isopropylamino propoxy) naphth-2-ylcarboxamido] pentyl)-(R, S) -alanyl- (S) -proline Or N- (1 (S) -carboxy-5- [4- (2 (S) -hydroxy-3-isopropylamino propoxy) -1H-indol-2-ylcarboxamido] pentyl)-(S ) -Alanyl- (S) proline, or half ester thereof, or physiologically acceptable salt thereof. A method of using the compound of formula (I) or a physiologically acceptable salt thereof as claimed in claim 1 for the prevention or treatment of the disease or disease syndrome referred to in claims 3 to 5. 8. A compound according to claim 7, wherein the compound of formula (I) or a physiologically acceptable salt thereof is N- (1 (S) -carboxy-5- [5- (2 (R, S) -hydroxy-3-isopropyl) Amino propoxy) naphth-2-ylcarboxamido] pentyl)-(R, S) -alanyl- (S) -proline, N- (1 (S) -carboxy-5- [8- (2 ( R, S) -hydroxy-3-isopropylamino propoxy) naphth-2-ylcarboxamido] pentyl)-(R, S) -alanyl- (S) -proline or N- (1 (S ) -Carboxy-5- [4- (2 (S) -hydroxy-3-isopropylamino propoxy) -1H-indol-2-ylcarboxamido] pentyl)-(S) -alanyl- (S ) -Proline, or its half ester, or physiologically acceptable salt. A pharmaceutical formulation containing a physiologically acceptable carrier and a compound of formula (I) as claimed in claim 1 or a physiologically acceptable salt thereof. ※ Note: The disclosure is based on the initial application.